Federal Register / Vol. 71, No.
246 / Friday, December 22, 2006 / Notices
August 15, 2006, (71 FR 46921), Dade
Behring Inc., 100 GBE Drive, MS514,
Post Office Box 6101, Attention: RA/QS,
Newark, Delaware 19714–6101, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
Drug
Tetrahydrocannabinols (7370) .....
Benzoylecgonine (9180) ...............
Morphine (9300) ...........................
The company plans to produce the
listed controlled substances in bulk to
be used in the manufacture of reagents
and drug calibrator/controls for DEA
exempt products.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of Dade
Behring Inc. to manufacture the listed
basic classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated Dade
Behrig Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: December 14, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–21870 Filed 12–21–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated August 7, 2006, and
published in the Federal Register on
August 15, 2006, (71 FR 46921), Dade
Behring Inc., Regulatory Affairs, Quality
Systems, 20400 Mariani Avenue,
Cupertino, California 95014, made
jlentini on PROD1PC65 with NOTICES
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
VerDate Aug<31>2005 19:31 Dec 21, 2006 Jkt 211001
77065
Drug
Tetrahydrocannabinols (7370) .....
Benzoylecgonine (9180) ...............
Morphine (9300) ...........................
The company plans to produce the
listed controlled substances in bulk to
be used in the manufacture of reagents
and drug calibrator/controls for DEA
Schedule exempt products.
No comments or objections have been
received. DEA has considered the
I
II factors in 21 U.S.C. 823(a) and
II determined that the registration of Dade
Behring Inc. to manufacture the listed
basic classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated Dade
Behrig Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with State
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: December 14, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–21871 Filed 12–21–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on November 15,
2006, Johnson Matthey Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066, made application by letter to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Remifentanil (9739), a
basic class of controlled substance listed
in schedule II.
The company plans on producing this
item for sale to its customers, who are
final dosage manufacturers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
PO 00000 Frm 00106 Fmt 4703 Sfmt 4703
Schedule Any such written comments or
objections being sent via regular mail
I should be addressed, in quintuplicate,
II to the Deputy Assistant Administrator,
II Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than February 20, 2007.
Dated: December 14, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–21884 Filed 12–21–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on October 31, 2006,
Johnson Matthey Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066, made application by letter to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of 14-
Hydroxymorphinone (9654), a basic
class of controlled substance listed in
schedule II.
The company plans to manufacture
the listed controlled substances in bulk
as an intermediate for use in the
production of another controlled
substance.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR § 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than February 20, 2007.
E:\FR\FM\22DEN1.SGM 22DEN1
 77066 Federal Register / Vol. 71, No. 246 / Friday, December 22, 2006 / Notices
Dated: December 14, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–21896 Filed 12–21–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances
Notice of Registration
By Notice dated July 19, 2006, and
published in the Federal Register on
July 26, 2006, (71 FR 42417), Meridian
Medical Technologies, 255 Hermelin
Drive, St. Louis, Missouri 63144, made
application to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Morphine (9300), a basic
class of controlled substance listed in
schedule II.
The company plans to import
products for research experimentation
or clinical use and analytical testing.
One objection was received; however,
it has subsequently been withdrawn.
DEA has considered the factors in 21
U.S.C. § 823(a) and § 952(a) and
determined that the registration of
Meridian Medical Technologies to
import the basic class of controlled
substances is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971, at this time. DEA has
investigated Meridian Medical
Technologies to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. § 952(a)
and § 958(a), and in accordance with 21
CFR § 1301.34, the above named
company is granted registration as an
importer of the basic class of controlled
substances listed.
Dated: December 14, 2006.
Joseph T. Rannazzisi,
jlentini on PROD1PC65 with NOTICES
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–21895 Filed 12–21–06; 8:45 am]
BILLING CODE 4410–09–P
VerDate Aug<31>2005 19:31 Dec 21, 2006 Jkt 211001
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on November 07,
2006, Organichem Corporation, 33
Riverside Avenue, Rensselaer, New
York 12144, made application by
renewal to the Drug Enforcement
Administration (DEA) as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
I and II:
Drug
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Pentobarbital (2270) .....................
Hydrocodone (9193) .....................
Meperidine(9230) .........................
Dextropropoxyphene (9273) .........
Fentanyl (9801) ............................
The company plans to manufacture
bulk controlled substances for use in
product development and for
distribution to its customers. In
reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabindiol as a synthetic
intermediate. This controlled substance
will be further synthesized to bulk
manufacture a synthetic THC (7370). No
other activity for this drug code is
authorized for this registration.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR § 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than February 20, 2007.
PO 00000 Frm 00107 Fmt 4703 Sfmt 4703
Dated:December 14, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–21886 Filed 12–21–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances Notice of Registration
By Notice dated July 25, 2006, and
published in the Federal Register on
July 31, 2006, (71 FR 43211), Penick
Corporation, 33 Industrial Park Road,
Schedule Pennsville, New Jersey 08070, made
application by renewal to the Drug
I Enforcement Administration (DEA) to
I be registered as a bulk manufacturer of
II the basic classes of controlled
II substances listed in schedule II:
II
II Drug Schedule
II
II Cocaine (9041) ............................. II
II Codeine (9050) ............................. II
Dihydrocodeine (9120) ................. II
Oxycodone (9143) ........................ II
Hydromorphone (9150) ................ II
Ecgonine (9180) ........................... II
Hydrocodone (9193) ..................... II
Morphine (9300) ........................... II
Thebaine (9333) ........................... II
Oxymorphone (9652) ................... II
The company plans to manufacture
the listed controlled substances as bulk
controlled substance intermediates for
distribution to its customers for further
manufacture or to manufacture
pharmaceutical dosage forms.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Penick Corporation to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Penick Corporation to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
E:\FR\FM\22DEN1.SGM 22DEN1